Genmab A/S (NASDAQ:GMAB) Shares Gap Down – What’s Next?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares gapped down prior to trading on Wednesday . The stock had previously closed at $34.40, but opened at $33.02. Genmab A/S shares last traded at $32.94, with a volume of 702,905 shares traded.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near‑term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near‑term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short‑interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full‑year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near‑term earnings visibility and are the primary reason investors are marking the stock down today.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on GMAB shares. Truist Financial restated a “buy” rating and issued a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $39.00 target price on shares of Genmab A/S in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.25.

Genmab A/S Stock Down 2.2%

The stock has a market cap of $20.96 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 18.54 and a beta of 0.90. The business’s 50-day simple moving average is $32.42 and its two-hundred day simple moving average is $28.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of GMAB. Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. CWM LLC lifted its holdings in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares during the period. NewEdge Advisors LLC lifted its stake in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the period. Brown Brothers Harriman & Co. lifted its stake in Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares during the period. Finally, Founders Capital Management boosted its holdings in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.